


AI in Drug Discovery and Development Market Size, Trends, Growth Forecast 2025–2033 | DataM Intelligence

The Global AI in Drug Discovery and Development Market is expected to reach at a CAGR of 18.5% during the forecast period 2025-2033.

AUSTIN, TX, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- The Global [AI in Drug Discovery and Development Market](#) was valued at \$6.24 billion in 2024 and is predicted to reach \$34.05 billion by 2033, increasing at a CAGR of 18.5% between 2025 and 2033.



Market Overview:

The AI in Drug Discovery and Development Market is expanding rapidly because of increased demand for precision medicine and the need to shorten R&D cycles. AI algorithms provide for speedier identification of drug candidates, improved clinical trial designs, and lower failure rates. The market is being molded by ongoing investments, strategic alliances, and regulatory backing for AI-driven advancements in medical sciences.

“

The AI in Drug Discovery and Development Market is expanding rapidly, driven by faster drug screening, precision medicine, and cost efficiency across preclinical and clinical stages.”

DataM Intelligence

Download Sample Report Here:

<https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market>

Market Drivers and Opportunities:

Data-Driven Precision Medicine: Increasing reliance on large-scale data analytics to develop

targeted therapies is a key growth driver.

Cost and Time Efficiency: AI helps reduce the average drug development cost and timelines, offering a competitive edge.

Growing Investment in Biotech Startups: Venture capital funding and government support are boosting the adoption of AI in biotech R&D.

AI-Powered Drug Repurposing: Growing potential for identifying new uses for existing drugs, especially in rare and complex diseases.

Expansion of Cloud-Based Infrastructure: Enhances access to computational power for AI model training and deployment.

Market Segmentation:

By Technology:

Machine Learning

Natural Language Processing

Generative AI

Others.

By Application:

Target Discovery & Validation

Hit Discovery & Virtual Screening

Hit-to-Lead

Lead Optimization

Pre-Clinical Testing

Clinical Trials

Others.

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East

Africa.

Stay ahead with data-driven strategies, competitive analysis, and future outlook.

Get the Extensive Full Report Now: <https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market>

Geographical Share:

North America dominates the market, with the U.S. leading in AI innovation and pharma-biotech collaboration.

Asia-Pacific is witnessing rapid growth, especially in Japan, due to strong R&D support and government initiatives.

Europe maintains a steady share, with countries like the UK and Germany focusing on regulatory compliance and AI ethics in medicine.

Key Players:

Prominent companies shaping the market include:

Alphabet (Google DeepMind)

Atomwise Inc.

BenevolentAI

BioMap

BioSymetrics

DEEP GENOMICS.

Euretos.

Exscientia

IBM

Iktos.

These players are focusing on AI platform development, drug screening, and partnering with academic institutions and biopharmaceutical giants.

Recent Developments:

United States

Atomwise announced a next-generation AI platform using quantum computing in February 2025 to accelerate target discovery for neurodegenerative illnesses.

August 2024 – Insilico Medicine announced a partnership with Pfizer to develop novel drug candidates using its AI platform for fibrosis-related disorders.

Japan

March 2025 – Astellas Pharma collaborated with Tokyo-based AI startup Elix, Inc. to enhance molecular property prediction and drug design pipelines.

September 2024 – Takeda Pharmaceuticals initiated an AI-driven platform with the University of

Tokyo to repurpose drugs for rare pediatric diseases.

Stay informed with the latest industry insights-start your subscription now:

<https://www.datamintelligence.com/reports-subscription>

Conclusion:

AI is revolutionizing the drug discovery and development landscape, transforming how treatments are researched, designed, and delivered. As global pharmaceutical companies and tech innovators converge, the market is set to experience sustained growth. With continuous advancements, regulatory encouragement, and increasing cross-border collaborations, AI is paving the way for the next era of efficient, data-driven drug innovation.

Related Reports:

[Generative AI in Healthcare Market](#)

[Artificial Intelligence in Healthcare Market](#)

Sai Kiran

DataM Intelligence 4Market Research

+1 877-441-4866

Sai.k@datamintelligence.com

Visit us on social media:

[LinkedIn](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/823694338>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.